Guided Therapeutics Enters Material Definitive Agreement

TL;DR

GTXI signed a big deal, details TBD.

AI Summary

Guided Therapeutics, Inc. announced on September 23, 2024, that it entered into a Material Definitive Agreement. The filing does not provide specific details about the agreement, its terms, or any involved parties or dollar amounts.

Why It Matters

This filing indicates a significant business development for Guided Therapeutics, Inc., though the lack of detail prevents immediate assessment of its impact.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about the nature and potential impact of the deal.

Key Players & Entities

• Guided Therapeutics, Inc. (company) — Registrant
• September 23, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $300,000 — f Directors, for the purpose of raising $300,000 in gross proceeds for the Company. Purs
• $0.09 — urchase price per Share and Warrant was $0.09. The Warrants are immediately exercisab
• $0.12 — ance date and have an exercise price of $0.12 per share. The closing of offering pur

Filing Documents

• gthp_8k.htm (8-K) — 25KB
• gthp_ex41.htm (EX-4.1) — 73KB
• gthp_ex101.htm (EX-10.1) — 171KB
• 0001477932-24-005960.txt ( ) — 445KB
• gthp-20240923.xsd (EX-101.SCH) — 6KB
• gthp-20240923_lab.xml (EX-101.LAB) — 13KB
• gthp-20240923_cal.xml (EX-101.CAL) — 1KB
• gthp-20240923_pre.xml (EX-101.PRE) — 8KB
• gthp-20240923_def.xml (EX-101.DEF) — 2KB
• gthp_8k_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement . On September 23, 2024, Guided Therapeutics, Inc. (the " Company ") entered into a Securities Purchase Agreement (the " Purchase Agreement ") with certain institutional investors (the " Investors "), including John Imhoff a member of the Company's Board of Directors, for the purpose of raising $300,000 in gross proceeds for the Company. Pursuant to the terms of the Purchase Agreement, the Company agreed to sell, in a private placement offering, an aggregate of 3,333,335 shares (the " Shares ") of the Company's common stock (" Common Stock ") and warrants (the " Warrants ") to purchase up to 3,333,335 shares of Common Stock (the shares of Common Stock issuable upon exercise of the Warrants, the " Warrant Shares "). The combined purchase price per Share and Warrant was $0.09. The Warrants are immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.12 per share. The closing of offering pursuant to the Purchase Agreement occurred on September 23, 2024. The Company intends to use the net proceeds from the transactions for general corporate purposes and working capital. The forms of the Purchase Agreement and the Warrant are filed as Exhibits 4.1 and 10.1, respectively, to this Current Report on Form 8-K. The foregoing summaries of the terms of these documents are subject to, and qualified in their entirety by, such documents, which are incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 4.1 Form of Warrant 10.1 Form of Securities Purchase Agreement 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GUIDED THERAPEUTICS, INC. Date: September 26, 2024 /s/ Mark Faupel By: Mark Faupel President and Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR